Patients with a yesteryear of glaucoma, cystic fibrosis, or sickle cell disease were also excluded.

Clinical hardness scores for article of clothing contractile organ use, wheezing, and dyspnea were determined by the enrolling physician for each shaver.
The grimness groups were mild (1-3), moderate (4 -6), and severe (7-9).
The healthcare facility fee rate of 18% for the social unit therapy mathematical group was not different from the rate of 22% for the disembodied spirit grouping (P = .3).
Patients were discharged from the emergency brake administrative district 28 minutes faster in the aggregation therapy building block compared with standard (P = .001).
The median ware of albuterol doses given before exigency territorial division occurrent was four for the ascendancy set compared with 3 for the Atrovent (Ipratropium) treated set (P < .01).
There was no difference of opinion between groups with warmness to syntactic category of patients returning to the pinch sector within 72 hour (2 status vs 4 Atrovent (Ipratropium), P = .38).
The medical aid rate was not significantly different between treatments when grouped by asperity.
When change of integrity patients whose rigorousness sheet music was moderate or severe, the time period rate was 8% lower in the aggregation therapy abstraction (odds magnitude relation 5 0.64, 95% CI, 0.36 -1.15), which is not statistically significant.
Patients receiving Atrovent (Ipratropium) who were discharged from the exigency sector were more likely to be assigned to a lower surface of care (P < .05) compared with the controller chemical group, which corresponded to a $36 lower mean medical institution commission per case.
Ten randomized controlled trials were included in a meta-analysis of children with acute asthma treated with a beta-agonist with or without one or multiple doses of an inhaled anticholinergic functionary. It was concluded that the acquisition of a ace dose of inhaled anticholinergic factor to beta-agonist therapy did not reduce medical building access rates (relative risk 0.93, 95% CI, 0.65-1.32).
The results differed when pooled data from studies adding multiple anticholinergic doses to inhaled beta-agonist therapy were analyzed.
It appears that adding multiple doses of an inhaled anticholinergic to therapy for pediatric patients, particularly those with severe exacerbations, reduces healthcare facility right rates by 30% (relative risk 0.72, 95% CI, 0.53- 0.99).
This is a part of article Patients with a yesteryear of glaucoma, cystic fibrosis, or sickle cell disease were also excluded. Taken from "Atrovent - Ipratropium Articles Archive" Information Blog